X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs STERLING BIOTECH - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA STERLING BIOTECH TORRENT PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 44.8 -0.4 - View Chart
P/BV x 6.1 0.0 42,677.5% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
STERLING BIOTECH
Dec-13
TORRENT PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,55011 14,761.9%   
Low Rs1,1443 33,632.4%   
Sales per share (Unadj.) Rs354.726.8 1,323.1%  
Earnings per share (Unadj.) Rs40.1-15.0 -267.9%  
Cash flow per share (Unadj.) Rs64.2-5.5 -1,175.6%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.154.9 497.7%  
Shares outstanding (eoy) m169.22267.87 63.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.80.3 1,464.5%   
Avg P/E ratio x33.6-0.5 -7,232.3%  
P/CF ratio (eoy) x21.0-1.3 -1,648.3%  
Price / Book Value ratio x4.90.1 3,893.5%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8971,862 12,241.4%   
No. of employees `00014.71.4 1,085.7%   
Total wages/salary Rs m11,353547 2,076.2%   
Avg. sales/employee Rs Th4,083.05,303.3 77.0%   
Avg. wages/employee Rs Th772.3403.8 191.2%   
Avg. net profit/employee Rs Th461.3-2,959.0 -15.6%   
INCOME DATA
Net Sales Rs m60,0217,181 835.9%  
Other income Rs m2,98843 7,015.0%   
Total revenues Rs m63,0097,223 872.3%   
Gross profit Rs m13,493947 1,424.9%  
Depreciation Rs m4,0862,543 160.7%   
Interest Rs m3,0854,377 70.5%   
Profit before tax Rs m9,310-5,931 -157.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529-1,924 -131.4%   
Profit after tax Rs m6,781-4,007 -169.3%  
Gross profit margin %22.513.2 170.5%  
Effective tax rate %27.232.4 83.7%   
Net profit margin %11.3-55.8 -20.2%  
BALANCE SHEET DATA
Current assets Rs m52,62314,335 367.1%   
Current liabilities Rs m52,02249,809 104.4%   
Net working cap to sales %1.0-494.0 -0.2%  
Current ratio x1.00.3 351.5%  
Inventory Days Days120403 29.6%  
Debtors Days Days76171 44.7%  
Net fixed assets Rs m85,01655,432 153.4%   
Share capital Rs m846268 315.9%   
"Free" reserves Rs m45,37613,935 325.6%   
Net worth Rs m46,22214,701 314.4%   
Long term debt Rs m41,1159,478 433.8%   
Total assets Rs m142,43273,988 192.5%  
Interest coverage x4.0-0.4 -1,132.0%   
Debt to equity ratio x0.90.6 138.0%  
Sales to assets ratio x0.40.1 434.2%   
Return on assets %6.90.5 1,382.9%  
Return on equity %14.7-27.3 -53.8%  
Return on capital %14.2-6.4 -220.9%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m14,5801,860 784.0%   
Fx outflow Rs m3,60025 14,463.2%   
Net fx Rs m10,9801,835 598.4%   
CASH FLOW
From Operations Rs m8,9421,719 520.3%  
From Investments Rs m-47,070-3,148 1,495.1%  
From Financial Activity Rs m34,1741,426 2,396.5%  
Net Cashflow Rs m-3,655-3 107,500.0%  

Share Holding

Indian Promoters % 71.5 33.9 210.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.0 -  
FIIs % 12.6 9.9 127.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.8 39.3 22.4%  
Shareholders   26,511 21,482 123.4%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  AUROBINDO PHARMA  PFIZER  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS